The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals

por Lachmann, P.J.
Publicado 2012

Immunology: Are complement lysis and lymphocytotoxicity analogous?

por Lachmann, P.J.
Publicado 1983

REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS : II. THE CHARACTERIZATION OF ACTIVATED REACTOR AS C56 AND THE PARTICIPATION OF C8 AND C9

por Lachmann, P. J., Thompson, R. A.
Publicado 1970

REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS : I. THE CHARACTERIZATION OF THE INDICATOR FACTOR AND ITS IDENTIFICATION AS C7

por Thompson, R. A., Lachmann, P. J.
Publicado 1970

THE LOCALIZATION OF IN VIVO BOUND COMPLEMENT IN TISSUE SECTIONS

por Lachmann, P. J., Müller-Eberhard, H. J., Kunkel, H. G., Paronetto, F.
Publicado 1962

A preliminary trial of a novel form of active immunotherapy in squamous cell carcinoma of the lung.

por Lachmann, P. J., Grant, R. M., Freedman, L. S., Sikora, K., Bleehen, N. M.
Publicado 1985

Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency(1)

por Ugrinovic, S., Firth, H., Kavanagh, D., Gouliouris, T., Gurugama, P., Baxendale, H., Lachmann, P. J., Kumararatne, D., Gkrania‐Klotsas, E.
Publicado 2020